JP2011510654A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510654A5
JP2011510654A5 JP2010545017A JP2010545017A JP2011510654A5 JP 2011510654 A5 JP2011510654 A5 JP 2011510654A5 JP 2010545017 A JP2010545017 A JP 2010545017A JP 2010545017 A JP2010545017 A JP 2010545017A JP 2011510654 A5 JP2011510654 A5 JP 2011510654A5
Authority
JP
Japan
Prior art keywords
antibody
hybridoma
antigen
fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010545017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510654A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000562 external-priority patent/WO2009105150A2/en
Publication of JP2011510654A publication Critical patent/JP2011510654A/ja
Publication of JP2011510654A5 publication Critical patent/JP2011510654A5/ja
Pending legal-status Critical Current

Links

JP2010545017A 2008-01-28 2009-01-28 有用な抗体を発現する雑種細胞の作成方法 Pending JP2011510654A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6258408P 2008-01-28 2008-01-28
PCT/US2009/000562 WO2009105150A2 (en) 2008-01-28 2009-01-28 Method of making hybrid cells that express useful antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015009809A Division JP5923186B2 (ja) 2008-01-28 2015-01-21 有用な抗体を発現する雑種細胞の作成方法

Publications (2)

Publication Number Publication Date
JP2011510654A JP2011510654A (ja) 2011-04-07
JP2011510654A5 true JP2011510654A5 (enExample) 2012-03-15

Family

ID=40986086

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010545017A Pending JP2011510654A (ja) 2008-01-28 2009-01-28 有用な抗体を発現する雑種細胞の作成方法
JP2015009809A Active JP5923186B2 (ja) 2008-01-28 2015-01-21 有用な抗体を発現する雑種細胞の作成方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015009809A Active JP5923186B2 (ja) 2008-01-28 2015-01-21 有用な抗体を発現する雑種細胞の作成方法

Country Status (4)

Country Link
US (1) US8999707B2 (enExample)
EP (1) EP2242836B1 (enExample)
JP (2) JP2011510654A (enExample)
WO (1) WO2009105150A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8557575B2 (en) 2008-01-28 2013-10-15 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
WO2010003529A1 (en) * 2008-06-16 2010-01-14 University Of Zurich Method of providing immunoglobulin secreting b lymphocytes and human antibodies
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
WO2011028962A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
SI2400298T1 (sl) * 2010-05-28 2013-11-29 F. Hoffmann-La Roche Ag Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
WO2012072814A1 (en) * 2010-12-02 2012-06-07 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
EP2724157B1 (en) 2011-06-27 2017-03-08 Valneva Method for screening cells
WO2013076139A1 (en) * 2011-11-23 2013-05-30 F. Hoffmann-La Roche Ag Cd40l expressing mammalian cells and their use
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
WO2014138733A2 (en) * 2013-03-08 2014-09-12 Dessain Scott K Compositions and methods for making human antibodies
US20160014600A1 (en) * 2014-07-10 2016-01-14 Bank Of America Corporation Identification of Potential Improper Transaction
US20160253708A1 (en) * 2015-02-26 2016-09-01 Dropbox, Inc. Method and system for efficiently serving upsell content based on complex user archetypes
JP2019506412A (ja) 2016-02-10 2019-03-07 ラトガース， ザ ステイト ユニバーシティー オブ ニュージャージー 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗−ＬＡＭおよび抗−ＰＩＭ６／ＬＡＭモノクローナル抗体
JP7252627B2 (ja) 2016-12-15 2023-04-05 デューク ユニバーシティ 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
BR112021006431A2 (pt) 2018-10-02 2021-07-27 Immunome, Inc. anticorpos direcionados a epn1
WO2022150809A1 (en) 2021-01-05 2022-07-14 Immunome, Inc. Antibody cocktail against sars-cov-2 spike protein
CN114350606A (zh) * 2022-01-05 2022-04-15 上海药明生物医药有限公司 一种富集大鼠浆细胞及建立浆细胞杂交瘤的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3150991B2 (ja) * 1991-04-10 2001-03-26 協和醗酵工業株式会社 ハイブリドーマの製造法
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US7491530B2 (en) 2001-12-18 2009-02-17 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
EP1692276B1 (en) * 2003-11-19 2010-07-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of inducing memory b cell development and terminal differentiation
EP1928999B1 (en) * 2005-08-23 2011-04-13 IQ Corporation Methods of producing stable b-lymphocytes
US8557575B2 (en) * 2008-01-28 2013-10-15 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies

Similar Documents

Publication Publication Date Title
JP2022177090A5 (enExample)
JP2022523442A5 (enExample)
JP2020534830A5 (enExample)
RU2020120539A (ru) Композиции для ингибирования masp-2-зависимой активации комплемента
JP2011526785A5 (enExample)
HRP20191697T1 (hr) Vezujuće molekule za bcma i cd3
KR20210100654A (ko) Cd3 항체 및 그의 약제학적 용도
JP2015508056A5 (enExample)
IL273196B1 (en) Claudin 6 antibodies and methods of cancer treatment
RU2012142230A (ru) Антитела против csf-1r человека и их применение
JP2013520984A5 (enExample)
JP2020504101A5 (enExample)
RU2012147638A (ru) Антитела против растворимого st-2 человека и способы анализа
HRP20131215T1 (hr) Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope
RU2014103784A (ru) Антитело, блокирующее agr2, и его применение
RU2012142231A (ru) Антитела против csf-1r человека и их применение
RU2008129111A (ru) Антитела к ox40l и способы их применения
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
NZ603226A (en) Anti-c5a antibodies and methods for using the antibodies
RU2009126766A (ru) Антитела человека к дельта-подобному лиганду-4 человека
RU2013142600A (ru) Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2012523848A5 (enExample)
JP2011527899A5 (enExample)
RU2012137380A (ru) Моноклональные антитела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи